Northwest Biotherapeutics Plans US Manufacturing Restart to Expand Production Capacity

• Northwest Biotherapeutics plans to restart US manufacturing to supplement or back up UK capacity under its Oct. 26, 2026, expansion strategy.
• Preparations for clinical trials in cancers beyond brain cancer are another operational priority.
• US staffing changes will produce a net headcount increase while keeping operating costs in the same range.
• Further US job cuts may target skills no longer needed for evolving priorities; one position has been eliminated.
• A similar UK staffing review will expand expertise needed for priority operations and scale-up while reducing other personnel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610261123PR_NEWS_EURO_ND__EN80969) on October 26, 2026, and is solely responsible for the information contained therein.